To add this meeting to your calendar please use the link found here. Note – you must be an ARCC member to access this link – Join Us for access

Please join us for an ARCC Webinar on Friday, August 14th at 1:00pm – 2:30pm (EST) / 10:00am – 11:30am (PST) / 2:00pm – 3:30pm (AST) / 11:00am – 12:30pm (MST) to hear Dr. Deborah A. Marshall, Dr. Yvonne Bombard and Dr. Maureen E. Trudeau discuss an ARCC supported project – Understanding risk-benefit trade-offs of genomic testing in chemotherapy treatment decisions for breast cancer.

Dr. Deborah A. Marshall, PhD


Dr. Marshall is an Associate Professor in the Department of Community Health Sciences, University of Calgary and the Director of Health Technology Assessment (HTA) at the Alberta Bone and Joint Health Institute and Associate Professor (part-time) in the Department of Clinical Epidemiology and Biostatistics at the Centre for Evaluation of Medicines at McMaster University. Her Canada Research Chair, Health Services and Systems Research is a HTA research programme involving synthesis of evidence, measurement of preferences, cost-effectiveness analysis, and decision modeling of health systems. Dr. Marshall has research experience in HTA agencies, academic institutions and industry settings in Canada, US and Europe. Dr. Marshall’s academic training includes a PhD from the School of Public Health at the University of North Carolina, Chapel Hill as an Alberta Heritage Foundation for Medical Research Scholar, an MSc in Health Services Research (University of Alberta) and a BSc in Biochemistry (University of Toronto).

Her peer-reviewed cancer research grants from the US National Institutes of Health / National Cancer Institute and the Ontario Institute for Cancer Research are focused in the areas of measuring patient preferences using conjoint analysis, personalized medicine, and cost-effectiveness modeling. She is a Project Leader of the Economics Project in the Center for Translational and Policy Research on Personalized Medicine (TRANSPERS –, dedicated to developing evidence-based information for patients and other stakeholders to objectively assess how personalized medicine can be most beneficial and efficient in improving health outcomes.

Dr. Marshall is an active member of the International Society for Pharmacoeconomics and Outcomes Research as a member of the Patient Preferences Special Interest Group and as President-Elect member of the Board of Directors. She was also a member of the CADTH/NCIC Working Group to develop cancer-specific economic evaluation guidelines, and the NCI Clinical Trials and Translational Research Advisory Board Cost-Effectiveness Analysis Working Group. She also serves on the editorial board of the International Journal for Technology Assessment in Health Care and The Patient.

Dr. Yvonne Bombard, PhD

Yvonne Bombard

Dr. Bombard is a CIHR new investigator and recent recipient of a CIHR Foundation grant. Yvonne Bombard received her Interdisciplinary doctorate in Medical Genetics at the University of British Columbia and completed postdoctoral fellowships at Yale University, Memorial Sloan-Kettering Cancer Center and the University of Toronto. Dr. Bombard is Scientist at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Assistant Professor at the Institute of Health Policy, Management and Evaluation at the University of Toronto and Visiting Investigator at Memorial Sloan-Kettering Cancer Center.

Dr. Bombard’s research program focuses on assessing the health outcomes, ethical and policy implications of integrating personalized medicine tests and technologies in health care. Specifically, she conducts mixed methods research that assesses the impact of emerging genomic tools and tests on patients, providers and health service use, to support effective knowledge translation and evidence-based policy development. Dr. Bombard also conducts public and patient engagement research to advance health technology assessment as well as health care and service delivery.

Dr. Bombard is involved in policy development in related areas, through the Cancer Quality Council of Ontario’s Personalized Medicine Steering Committee, Cancer Care Ontario’s Patient Experience and Performance Committee, the Ontario Health Technology Advisory Committee’s Citizen Reference Panel and the Canadian Coalition for Genetic Fairness.
Dr. Bombard’s research has been published in genetics, social science and general medicine journals. She is also a frequent contributor and commentator in both the broadcast and print media, most recently being featured on CBC’s The Current. In 2011, Dr. Bombard received a ‘Rising Star’ award from CIHR’s Institute of Health Services and Policy Research.

Dr. Maureen E. Trudeau, MA, MD, FRCPC

Maureen Trudeau Headshot

Dr. Trudeau’s research interests cover the spectrum of breast cancer from prevention to treatment and palliative care. To date, her research has centred on the following:

– Clinical trials in prevention, and adjuvant and metastatic disease, including investigational new drugs
– A study of the quality of life and general health of long-term survivors of breast cancer
– Guidelines for the treatment of breast cancer and systemic therapy.

Her research findings have been published in many journals, including The New England Journal of Medicine, Journal of Clinical Oncology and Breast Cancer Research and Treatment.

In addition, Dr. Trudeau participates in clinical trials through the National Cancer Institute of Canada-Clinical Trials Group ,(NCIC-CTG), the National Surgical Adjuvant Breast and Bowel Project and in studies supported by grants from industry. She has also chaired several studies in breast cancer through NCIC-CTG.

The use of new drugs remains a strong area of research interest for Dr. Trudeau. She is investigating the use of epirubicin and Taxotere as a neoadjuvant therapy, and has collected tissue biopsies for microarray analysis of factors to predict drug sensitivity and resistance. This trial has formed the basis for further research in RNA degradation.

As co-chair of the Breast Disease Site Group, Dr. Trudeau has authored many guidelines on the treatment of breast cancer, which have influenced drug-funding decisions provincially and nationally.

Related Publications:

  1. Bombard Y, Rozmovits L, Trudeau M, Leighl NB, Deal K, Marshall DA. The value of personalizing medicine: Medical oncologists’ views on gene expression profiling in breast cancer treatment. The Oncologist. In press.
  2. Bombard Y, Rozmovits L, Trudeau M, Leighl NB, Deal K, Marshall DA. Patients’ perceptions of gene expression profiling in breast cancer treatment decisions. Current Oncology. 2014; 21(2): e203-11. doi: 10.3747/co.21.1524
  3. Bombard Y, Rozmovits L, Trudeau M, Leighl NB, Deal K, Marshall DA. Access to personalized medicine: Factors influencing the use and value of gene expression profiling in treatment decision-making. Current Oncology. 2014; 21(3): e426-33. doi: 10.3747/co.21.1782